Emergent BioSolutions, Inc., a biopharmaceutical company, engages in the development, manufacture, and commercialization of vaccines and therapeutics for use in defense and commercial markets to healthcare providers and purchasers in the United States and internationally. It markets BioThrax, a vaccine for the prevention of anthrax disease. The company’s products also include BioThrax PEP, which is in Phase III clinical trials; PreviThrax ands Anthrivig that are in Phase II clinical trials; and NuThrax and Thravixa, which are in Phase I clinical trials for the treatment of Anthrax. In addition, it develops MVA-85A, a prophylactic recombinant tuberculosis vaccine that is Phase II clinical trials; and SBI-087, which is in Phase II clinical trials for the treatment of rheumatoid arthritis and is in Phase I clinical trials to treat systemic lupus erythematosus. Further, the company develops TRU-016 that is in Phase II clinical trials to treat chronic lymphocytic leukemia and is in Phase I clinical trials for the treatment of non-Hodgkin's lymphoma; and Zanolimumab, which is in Phase I clinical trials to treat peripheral T-cell lymphoma; and is in Phase II clinical trials for the treatment of cutaneous T-cell lymphoma. Additionally, its products include SMIP and SCORPION protein therapeutics in preclinical development comprising ES301 (anti-CD3 SMIP protein), X2 (anti-CD86 x IL-10 SCORPION protein), and T-Scorp molecules targeted for solid organ transplant, inflammatory bowel disease, solid tumors, and rheumatoid arthritis; and an influenza vaccine. The company has agreements with USAMRIID, OETC, and Pfizer. Emergent BioSolutions, Inc. was founded in 1998 and is based in Rockville, Maryland.